| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_81014afb03be9194cc301ca46859a467
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f6022e7ac2356c5f7dee07a26a2f21a6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fe9f19dc1e5e6596c9f6070fc03dcf0a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_41cf442288d04037646863a41cbeb0fe |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4453
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0693
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-067
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5375 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 |
| filingDate |
2012-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b408f6dee082fa29f3c5369f3d173d95
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32261154b51c413681bec7f798326091 |
| publicationDate |
2014-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8633195-B1 |
| titleOfInvention |
Method of inhibiting apolipoprotein-E expression comprising administering a triarylmethyl amine compound |
| abstract |
This invention offers an effective method of inhibiting the expression of apolipoprotein E by mammalian cells. Apolipoprotein E is a protein that plays a significant role in the development of Alzheimer's Disease in humans. The method comprises administering an effective amount of a triarylmethyl amine compound having the general formula: n nwherein the R 1 group may comprise acyclic amines and aliphatic amines. The R 2 group may comprise one of three aryl varieties: aryl, substituted aryl, or heterocycle. Triarylamine compounds inhibit apolipoprotein E expression in mammalian cells. In one aspect of the invention the mammalian cells may be human cells, and more specifically may be human brain cells. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10214502-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018093960-A1 |
| priorityDate |
2012-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |